Mast cells are powerful immune modulators of the tissue microenvironment. Within seconds of activation, mast cells release a great variety of preformed biologically active products, followed by a wave of mediator synthesis and secretion. Increasing evidence suggests that an intricate network of inhibitory and activating receptors, specific signalling pathways and adaptor proteins governs mast cell responsiveness to stimuli. Here, we discuss the biological and clinical relevance of negative and positive signalling modalities that control mast cell activation, with emphasis on novel FcεRI-regulators, IgE-independent pathways (e.g., MRGX2 receptor), tetraspanins and the CD300 family of inhibitory and activating receptors.
Fine Tuning Mast Cell Activities
Mature mast cells are heterogeneous, tissue-resident, long-lived, granulated cells, which increase in number in inflammatory conditions by proliferation, increased recruitment, survival and/or maturation from mast cell progenitors. Particularly abundant at barrier sites, mast cells are among the fastest immune cell responders. They rapidly release preformed mediators, such as vasoactive amines (histamine and serotonin), proteoglycans, proteases, and cytokines from intracellular stores upon crosslinking of FcεRI (see glossary) bound immunoglobulin E (IgE) by allergens, infectious agents and toxins. Furthermore, mast cells, activated in an IgE-independent manner, shape their tissue microenvironment, engage in cell-cell interactions and contribute to the defence against, and clearance of various pathogens by secreting a wide array of de novo synthesized pro-inflammatory and antiinflammatory products [1] [2] [3] .
The molecular regulation of mast cell activation by FcεRI-mediated signalling via immunoreceptor tyrosine-based activation motifs (ITAMs) has been investigated in depth in the past. Inhibitory receptors, generally characterized by the presence of immunoreceptor tyrosine-based inhibitory motifs (ITIMs which recruit SH2-domain containing phosphatases, have been identified as cardinal regulators of mast cell activation. Among them are the inhibitory low-affinity IgG receptor FcγRIIB, the CD200R and a number of Ig-like receptors [4] . However, other signals, including non-ITIM containing inhibitory receptors (e.g. catecholamine-binding, β2-adrenergic, and ATP or adenosine-binding, purinergic, receptors) as well as anti-inflammatory cytokines (e.g. IL-10 and TGFβ) can also antagonize mast cell activation and mediator secretion [5, 6] , underlining the complex regulation of signalling in these cells.
In this review we focus our attention on novel mechanisms that act at various levels and by diverse means, to adjust mast cell activities in order to tune inflammation up or down as needed to avoid mast cell disorders such as allergy, mastocytosis and autoimmunity.
FcεRI-Mediated Signalling: an Intricacy of Positive Signalling and Inhibitory Players
Evidence has accumulated in recent years introducing the novel concept that (patho)physiological IgE responses vary between individuals and that a number of parameters fine-tune mast cell responsiveness: polyclonality of the IgE repertoire, number of epitopes recognized, their distance from each other and antigen affinity [7, 8] . Moreover, it has become clear that autoantibodies (anti-IgE or IgE) may impact on pathology development [9] [10] [11] .
It was established early on that aggregates of receptor bound IgE as small as a dimer were sufficient to induce secretory responses [12] . Although this was questioned by the discovery that monomeric IgE can induce mast cell survival and potentiation of cytokine responses [13, 14] follow-up studies demonstrated that the effects of monomeric IgE are caused by aggregation that could be prevented in the presence of carrier-free hapten [15] . Another study examined secretory responses as a function of antigen concentration and showed that low antigen concentrations favoured chemokine secretion in the absence of visible degranulation, while at high antigen concentrations both responses became apparent ( [16] and Figure 1A , left). Weak stimulation favoured the phosphorylation of GRB2-associated protein binding 2 (GAB2) and p38 mitogen-activated protein kinase (MAPK), while linker for activation of T cells (LAT1) and extracellular-signal regulated kinase 2 (ERK2) phosphorylation was favoured by a stronger stimulus. In allergic patients, mast cell degranulation induced by allergens was shown to poorly correlate with the allergen-specific IgE content [17] . These studies have challenged the simplistic view of a unique positive forward response and support the concept that the outcome of receptor triggering can be quite variable. They argue against a kinetic proofreading mechanism controlled by the appropriate lifetime of receptor clusters for a given functional response [18] . Rather they favour the hypothesis of a differential coupling of signalling effectors in response to antigen. Such differential molecular editing was demonstrated in carefully controlled analysis of responses to antigens of different affinities [19] . Triggering of FcεRI-bound monoclonal IgE upon interaction with a low affinity antigen (adjusted to a similar total tyrosine phosphorylation response) differed from responses observed with the high affinity antigen, namely favouring chemokine secretion over degranulation and cytokine production ( Figure 1A, right) . At the same time the dynamics and mobility of FcεRI clusters were markedly reduced with aggregated receptors exhibiting a differential spatial distribution. Low affinity antigen binding promoted adapter LAT2 phosphorylation instead of LAT1 and favoured recruitment of the Src family kinase FGR, while recruitment of the kinase LYN remained unaltered. In vivo, during a passive cutaneous anaphylaxis response, this differential responsiveness translated to an altered cell recruitment at the inflammatory site. Besides antigen concentrations and affinity, the distance of epitopes recognized by IgE is also a crucial parameter [20] . This was shown by engineering epitopes onto a protein carrier at different distances. This resulted in different shapes of the resulting IgE immune complexes as examined by negative-stain electron microscopy. The study confirmed that the magnitude of functional responses was greater with antigens of higher valency [21] , but also that close proximity also increased the potency of the response.
Importantly, many studies demonstrated that FcεRI triggering can also deliver an inhibitory response. Indeed, challenge of mast cells under permissive conditions with increasing amounts of low dose antigen rapidly induces desensitization, a principle exploited in clinics to rapidly desensitize patients, notably to drugs [22, 23] . Although receptor internalization was initially proposed as a causative mechanism [22] , later analysis convincingly showed that desensitization rather affected intrinsic signalling responses, including phosphorylation of STAT6 and p38 MAPK, calcium mobilization as well as late responses such as lipid mediator or chemokine/cytokine release [24] . Recent signalling analyses have now shown that certain events such as LYN and LAT1 phosphorylation are still intact, while the calcium response is completely blunted due to a defect in actin rearrangement known to be required for calcium mobilization [25, 26] . Desensitization is antigen specific, since stimulation with a different antigen still triggers responses in sensitized cells [24, 26] . However, using a procedure targeting all cell surface receptors with anti-FcεRI monoclonal antibodies (mAbs), desensitisation can be achieved for a broad range of antigens [27] . Desensitization under low valency conditions has previously been observed for related IgA and IgG Fc receptors, a phenomenon described as inhibitory ITAM (ITAMi) signalling [28, 29] . However, it still remains to be investigated whether this mechanism is operative in FcεRI desensitisation and whether it can be inhibitory on heterologous receptors to deliver powerful general antiinflammatory effects as demonstrated for ITAMi signalling [28, 30, 31] . In addition to the direct regulation of signalling at the level of FcεRI, many other surface receptors and The first notion that tetraspanins could regulate signalling pathways in mast cells came from experiments in which anti-CD81 mAb blocked antigen-mediated degranulation in rat basophilic leukaemia cells and passive cutaneous anaphylaxis (PCA), a classical system for studying mast cell activation in vivo. Interestingly, anti-CD81 had no effect on antigeninduced tyrosine phosphorylation of numerous substrates, calcium mobilization and leukotriene C4 production [36] . Another anti-tetraspanin mAb, anti-CD63, also inhibited degranulation without any effect on global tyrosine phosphorylation and calcium response, but impaired the GAB2-phosphatidyl inositol 3 kinase (PI3K) pathway, that is known to be essential for both degranulation and adhesion. The inhibitory effect of anti-CD63 was observed in adherent cells, but not in cells in suspension, suggesting that CD63-integrinfibronectin axis is involved in the inhibition [37] . When mouse bone marrow-derived mast cells (BMMCs) from CD63-deficient mice were examined, a significant decrease in FcεRI-mediated degranulation, but not phorbol 12-myristate 13-acetate/ionomycin-induced degranulation was observed. These data suggested that CD63 may be required for generation of so far undefined FcεRI proximal signalling events that feed membrane fusion processes. Reconstitution of mast cell-deficient Kit w/w-v mice with CD63-deficient mast cells led to significantly attenuated PCA, confirming a positive regulatory role for CD63 on mast degranulation under physiological conditions [38] . How exactly CD63 regulates FcεRI signalling is not known, but it could be related to the finding that CD63 can recruit the calcium sensor synaptotagmin VII to lysosomes [39] .
A different phenotype was observed in BMMCs from CD151 -/-mice [40] , which exhibited normal antigen-induced degranulation, but significantly enhanced expression of the proinflammatory cytokines TNF-α, IL-4 and IL-13. Mice deficient in CD151 exhibited an enhanced PCA reaction, supporting the concept that CD151 is a negative regulator of the FcεRI-mediated signalling events in mast cells. Additional mechanistic studies showed that CD151 negatively regulated the ERK1/2-PI3 kinase-AKT signalling pathway without affecting phospholipase Cγ1 activation and calcium response [40] .
Although mice deficient in CD9 expression were generated more than 17 years ago [41] , studies on CD9 -/-mast cells are very limited. Interestingly, when wild-type BMMCs were exposed to a CD9-specific mAb, 2H9, the cells exhibited enhanced calcium mobilization and degranulation [42] . Antibody-mediated aggregation of CD9 also induced enhanced tyrosine phosphorylation of ERK, p38 MAP kinase and the transmembrane adaptor proteins LAT1 and especially LAT2. 2H9 mAb inhibited chemotaxis towards antigen. This inhibitory effect was observed after treatment with F(ab) 2 fragment but not with Fab fragment, suggesting that chemotaxis inhibition requires CD9 aggregation but is independent of co-cross-linking of CD9
with the inhibitory FcγRIIB (that is specific for the Fc portion absent in F(ab) 2 fragments). In
BMMCs with siRNA-mediated CD9 knockdown, migration towards antigen was not affected [42] . The observed inhibition of antigen-mediated chemotaxis by 2H9 mAb or its F(ab) 2 fragment could be related to the ability of CD9 to associate with integrin molecules [43, 44] .
A recent study showed that CD9 and CD63 are not equally distributed on extracellular vesicles released from mast cells [45] . Vesicles constitutively released from unstimulated cells were CD9 positive, whereas vesicles released from antigen-activated cells were smaller, CD63 positive, and exhibited a higher buoyant density, distinct phospholipid composition, and higher amount of mast cell specific proteases. These and other findings [46] The CD300 family of receptors has eight human members and nine mouse members. This family contains IRs and ARs, and is expressed by many immune cells, and notably by mast cells [49] . Of the CD300 family, human and mouse CD300a and CD300c are the only welldefined paired receptors, sharing around 80% homology. Importantly, three members of the human (CD300a, CD300c and CD300f) and four of the mouse CD300 family, namely CD300a Table 1 , and Figure 1C ).
The best-defined ligands for human CD300a are phosphatidylserine (PS) and phosphatidylethanolamine (PE) [50] . PS and PE are expressed on apoptotic cells, on tumour cells and on the external leaflet of the plasma membrane of activated and viral infected cells, suggesting CD300a-mediated regulation under these conditions. Additional ligands for the CD300 members are ceramide, TIM1 (T-cell immunoglobulin and mucin domain 1) and sphingolipids ( Figure 1C ).
Munitz, A et al., were the first to demonstrate that CD300a (recently reviewed in [51] ) is displayed on mast cells, eosinophils and basophils, acting to decrease their FcεRI-mediated activation [52] [53] [54] [55] . Later, it was demonstrated that DNAM1 (an activating receptor)-mediated activation of mast cells is completely blocked by CD300a activation [56] . The mechanisms of the inhibition rely on the anti-CD300a induced phosphorylation of the phosphatases SHP-1 and SHIP-1 and consequently dephosphorylation of a number of signal transduction molecules including SYK, LAT and KIT [49, 50] . Furthermore, it was shown, using chemically-generated bi-specific antibodies against CD300a and IgE and against CD300a and KIT, that CD300a inhibits mast cell activation and survival mediated by IgE-dependent mechanisms and by stem cell factor (SCF) [57, 58] . Therefore, selective targeting of CD300a on mast cells could be an effective immune-pharmacological method of treating mast cellassociated diseases.
Using a CD300c specific mAb [59] it was shown that CD300c is highly expressed in human mast cells and that after cross-linking leads to cytokine production. Furthermore, it was demonstrated that both CD300a and CD300c interact with PE producing a dominant inhibitory interaction [59] . The same group also found that CD300f, whose ligands are sphingomyelin and ceramide, is expressed on mast cells, inhibiting their FcεRI activation [60] .
CD300a is expressed on mouse mast cells and in a model of allergic peritonitis its neutralization with specific antibodies resulted in a significant increase in inflammatory mediators and eosinophilic infiltration [52] . On the other hand, specific targeting of CD300a with IgE or with CC chemokine receptor 3 (CCR3), using a bispecific antibody, significantly decreased airway inflammation and tissue remodelling and SCF induced cutaneous anaphylaxis [57, 61] .
CD300a knockout mice were generated by the Shibuya group [62] , who showed that CD300a delivers an inhibitory signal in mast cells to suppress production of lipopolysaccharide (LPS)-induced inflammatory cytokines and chemokines. Surprisingly, an opposite picture was seen in an experimental allergic airway inflammation model induced by alum with ovalbumin. In CD300a-deficient mice, eosinophil infiltration, serum IgE levels, and airway hyper-reactivity were significantly decreased after challenge [63] , possibly because dendritic cells in the CD300a-deficient mice produced less IL-4.
CD300lf is another negative regulator of mast cell activation following interaction with ceramide [64] and PS [65] . Under certain conditions, CD300If can amplify immune responses [66] . The intracellular tail of CD300lf has both ITIM and activating motifs, like PI3K binding motifs, highlighting the complexity in the ligand binding and signalling properties mediated by the CD300 family of receptors. Indeed, CD300lf-deficient mice showed enhanced allergic responses including anaphylaxis, airway inflammation, and dermatitis [67] . Interestingly, it was recently demonstrated that mast cells play an important role in dextran sulphate sodium (DSS)-induced colitis, as in the absence of CD300If (the experiment included transplanted mice lacking CD300IF only in mast cells), colitis in mice was exacerbated [68] .
Furthermore, it was reported that ceramide-CD300If interactions inhibited ATP-stimulated activation of BMMCs [68] . In contrast, upon association with FcRγ it switches its function to become an activating receptor in the presence of TLR4 stimulation [69] .
CD300lb, is another CD300 member expressed on mast cells and is a DAP12-coupled AR, binding TIM1, PS and LPS [70] . Stimulation with TIM1 induced CD300lb mediated activation of mast cells [71] . Cross-linking of CD300lb induced SYK-dependent activation of fetal liverderived mast cells [72] . CD300lh is highly expressed in BMMCs and found to associate with
FcRγ and its engagement induced cytokine production [73] .
While it is still unclear why CD300f and CD300a enhances mast cell activity under certain conditions this emphasizes the need for the generation of cell specific knockout mice of all of the above mentioned receptors and the necessity to fully understand the signalling mechanisms governing the activities of the CD300 receptors. Furthermore, it might be that under certain conditions, other members of the CD300 family are expressed, and/or pair with each other, or even bind additional ligands. Certainly, more research is required to fully understand the exact function of the CD300 family in controlling immune responses in general and allergy in particular.
Broad-Ranging Ligands Reconvening to a Shared MRGX2 Receptor-Mediated Signalling
Mast cells express several G protein-coupled receptors (GPCRs), which constitute the largest class of receptors in eukaryotes (i.e. approximately 800 identified in humans [74] ). Several of the well-known mast cell secretagogues, e.g., complement, neuropeptides, endothelin, host defense peptides or venoms bind to a GPCR and induce mast cell exocytosis and release of mediators. One GPCR that has received a lot of attention lately is the Mas-related G proteincoupled receptor X2 (MRGPRX2) [75] . MRGPRX2 was first identified in neurons of the dorsal root ganglion, and later it was recognized that mast cells appear to be the only cell besides dorsal root ganglion to express this receptor. Detailed transcriptomic analysis revealed that MRGPRX2 is selectively and highly expressed in human skin mast cells [76] . Similarly, the mouse ortholog MRGPRB2, is selectively expressed in mast cells [77] . Hence, besides its expression in dorsal root ganglia, MRGPRX2 has emerged as a unique and specific mast cell receptor.
MRGPRX2 appears to be mainly expressed in the MC TC type of mast cells [78] , which is the predominant mast cell type of the skin. In the lung and gut the tryptase-only containing mast cells MC T dominate, although some MC TC can be found in lower frequency. Although heterogeneity in reactivity to basic peptides, such as compound 48/80 and substance P, between MC TC and MC T has been recognized for a long time [79] , it was with the discovery of the MRGPRX2 that a mechanism for this heterogeneity was revealed [78] . Besides MRGPRX2, there are indications that substance P might also activate mast cells through the substance P receptor Neurokinin 1-receptor [80] . Several other peptides activate mast cells through MRGPRX2 including somatostatin, angiopeptin, mast cell degranulating peptide (MCDP) [78] and host defense peptides such as β-defensins [81] , as well as eosinophil major basic protein and peroxidase [82] . Of particular interest is that pseudoallergic responses to peptidergic-drugs are induced through activation of MRGPRX2 [83] . For example, icatibant, a bradykinin B2 receptor antagonist used for the treatment of hereditary angioedema, causes mast cell activation and release of histamine [84] . Other examples are neuromuscular blocking drugs when injected to reduce muscle movement during surgery [85] . In addition,
antibiotics of the fluoroquinolone family can also induce histamine release and allergic reactions [86] . Using a mouse model where the mouse ortholog to the human MRGPRX2, the MRGPRB2, was mutated, McNeil et al. could demonstrate that these three classes of drugs activate mast cells through MRGPRB2 and that mice lacking functional MRGPRB2
exhibit significantly reduced in vivo responses to these drugs compared with wild-type mice [83] .
In contrast to allergic, IgE-FcεRI-dependent, cutaneous reactions that often are long-lasting, pseudoallergic reactions, i.e., MRGPRX2-dependent, appear to be more transient. A plausible explanation for this apparent difference between these two activation pathways was described, recently [87] . Substance P, which activates MRGPRX2, induced a rapid, almost immediate, secretion of small and relatively spherical granules, presumably representing individual mast cell granules (Fig. 1D) . In contrast, FcεRI-mediated activation caused a delayed secretion of larger and more heterogeneously shaped granules, most likely due to granule fusion. Inhibition of IKK-β during the IgE-dependent activation, inhibited the SNAP23/Syntaxin-4 fusion process, and switched the pattern into one that resembled the substance P-induced mast cell degranulation. In vivo studies demonstrated that MRGPRX2-mediated degranulation induced a more rapid and transient vascular reaction compared to the more intense and prolonged response after FcεRI-activation [87] .
The identification of MRGPRX2 as a mast cell restricted receptor that induces degranulation and release of mediators in a distinct fashion with spherical granules that appear to be unstable, in contrast to the fused granules that are released after IgE-dependent activation ( Figure 1D ), has provided important information about the function of this receptor in health and disease. Besides pseudo-allergic reactions induced by certain drugs, this receptor is most likely involved in pathological conditions such as neurogenic inflammations and chronic urticaria [78, 82] . Skin mast cells in patients with chronic urticaria express increased levels of MRGPRX2 [82] . Together with the findings that substance P and eosinophil-released products activate skin mast cells via MRGPRX2 this suggests that this pathway contributes to the pathogenesis [82] . Thus, MRGPRX2 might be a new target molecule for the treatment of wheal reactions in patients with severe chronic urticaria and for circumvention of pseudoallergic reactions upon treatment with certain drugs. Whether the activity of the GPCRs, including MRGPRX2, expressed on mast cells are regulated by the tetraspanins and the IRs and ARs discussed above remains to be elucidated.
Concluding Remarks and Future Perspectives
In this review, we have highlighted negative and positive signals that control mast cell activation, focussing on modalities which control FcεRI signalling and on IgE-independent pathways such as the one driven by MRGX2 receptor engagement. We synthesize a complex
FcεRI signalling network where CD300 family members, using proper self-initiated, allergenindependent signalling, act as co-receptors to potentiate or dampen allergen-mediated mast cell activation.
It is becoming evident that a defined spatial organization involving the compartmentalization of receptors in specialized mast cell membrane domains and their linkage to the underlying cytoskeleton and signalling molecules is essential for proper activation. In mast cells, tetraspanins such as CD9, CD63, CD81 and CD151 not only serve as such guarantors of cell membrane structural integrity, but also exhibit significant crosstalk with FcεRI signalling events.
What remains still largely unclear are the internal signalling routes that decide on signal diversification by channelling the information from activated receptors into distinct biological functions such as preferential degranulation versus mediator secretion. Likewise, the direct or indirect "ranking" of signals that control synchronization, strength and velocity of mast cell activation or desensitization are still ill-defined, and the hierarchy and choreography of these signals in defined mast cell populations and signalling milieus remains essentially unknown and may be difficult to predict. Likely, to better grasp this, a systems biology approach to mast cell activation will be indispensable. activation. This discrepancy was important because PAG phosphorylation is thought to anchor C-terminal Src kinase, an inhibitor of Src kinases, which should therefore prevent rather than promote, FcεRI signalling in activated mast cells [88] . This matter has been recently resolved using quantitative phosphoproteomic analysis. In this study it was shown that TCR-mediated activation of resting T cells leads to enhanced PAG phosphorylation [89] , as seen in mast cells indicating that PAG could have both positive and negative roles in immunoreceptor signalling [90] . Another example of the facility of new technologies in mast cell biology is the recent identification, using next generation sequncing, of distinct extracellular RNA signatures released by mast cells in culture [91] . New methodological approaches will undoubtedly deepen our understanding of the molecular pathobiology of allergies and other inflammatory diseases and will facilitate the development of new drugs for mast-cell mediated diseases. PCA: passive cutaneous anaphylaxis is a method for analysis of mast cell function in vivo. In a typical PCA, IgE is injected intradermally where it binds to and locally sensitizes mast cells.
Next day antigen specific for the IgE and Evans blue are injected intravenously. Binding of the antigen to IgE-sensitized mast cells leads to mast cell degranulation, followed by increased permeability of vessels and Evans blue extravasation.
